Private company

TCR2 THERAPEUTICS INC.

American biological products company based in Cambridge, active since 20152

In its 2023 annual report the company says: “We are a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with our proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells).”48

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address100 Binney Street, Cambridge, Ma 021423
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493007TR1ORJAZ8YK342
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 57563002

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$153.5M in 2022+480% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$26.5M-$26.5M20182019: -$51.4M-$51.4M2019+94%2020: -$68.7M-$68.7M2020+34%2021: -$99.7M-$99.7M2021+45%2022: -$153.5M-$153.5M2022+54%
Net income4567-$151.8M in 2022+526% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$24.3M-$24.3M20182019: -$47.6M-$47.6M2019+96%2020: -$67.1M-$67.1M2020+41%2021: -$99.8M-$99.8M2021+49%2022: -$151.8M-$151.8M2022+52%
Fiscal year2017201820192020202120222023
Research and development$19.7M4$37.5M5$52.0M6$73.6M7$98.6M7
Operating expenses$99.7M7$153.5M7
Operating income-$26.5M4-$51.4M5-$68.7M6-$99.7M7-$153.5M7
Income before tax-$99.5M7-$151.6M7
Income tax$102.0K5$161.0K6$289.0K7$261.0K7
Net income-$24.3M4-$47.6M5-$67.1M6-$99.8M7-$151.8M7
Earnings per share-$2.637-$3.937
Earnings per share (diluted)-$2.637-$3.937
Shares (weighted, basic)37.9M shares738.6M shares7
Shares (weighted, diluted)37.9M shares738.6M shares7

Compare TCR2 THERAPEUTICS INC. with another company

Corporate structure

TCR2 THERAPEUTICS INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of TCR2 THERAPEUTICS INC.

  • TANG CAPITAL PARTNERS LP Filed SC 13G/A on TCR2 THERAPEUTICS INC., latest Feb 14, 2024 (4 filings since Mar 4, 2022)
  • K2 PRINCIPAL FUND, L.P. Filed SC 13G/A on TCR2 THERAPEUTICS INC., latest Feb 9, 2023 (2 filings since Sep 1, 2022)
  • Redmile Group, LLC Filed SC 13G/A on TCR2 THERAPEUTICS INC., latest Feb 14, 2022
  • Wellington Management Company Filed SC 13G/A on TCR2 THERAPEUTICS INC., latest Nov 10, 2021
  • TCR2 THERAPEUTICS INC. Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What TCR2 THERAPEUTICS INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$12.3M7 Dec 31, 2022$21.7M7 Dec 31, 2021−43.4%
Accumulated depreciation$6.1M7 Dec 31, 2022$4.6M7 Dec 31, 2021+32.3%
Property and equipment, net$6.2M7 Dec 31, 2022$17.1M7 Dec 31, 2021−63.9%
Operating-lease assets (leased space)$22.5M7 Dec 31, 2022$28.3M7 Dec 31, 2021−20.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$32.7M7 Dec 31, 2022$222.6M7 Dec 31, 2021−85.3%
Marketable securities, current$116.4M7 Dec 31, 2022$43.0M7 Dec 31, 2021+170.6%
Debt securities available for sale$43.0M7 Dec 31, 2021$133.8M6 Dec 31, 2020−67.8%

Leadership

Who has led TCR2 THERAPEUTICS INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Garry E. Menzel2019–2023

President

  1. Garry E. Menzel2019–2023

Chief financial officer

  1. Mayur Ian Somaiya2019–2020
  2. Eric Sullivan2022–2023

Chief operating officer

  1. Peter Olagunju2023
20202025
Board members and other officers (14)

Timeline

  1. Jun 1, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights28
  2. May 30, 20238-K Shareholder vote29
  3. May 24, 20238-K Entered a material agreement30
  4. May 22, 20238-K Other events31
  5. May 11, 20238-K Results of operations32
  6. Mar 23, 20238-K Results of operations33
  7. Mar 10, 20238-K Regulation FD disclosure34
  8. Mar 6, 20238-K Entered a material agreement; Executive or director change; Regulation FD disclosure35
  9. Jan 5, 20238-K Exit or restructuring costs; Regulation FD disclosure36
  10. Jan 3, 20238-K Executive or director change37
  11. Nov 8, 20228-K Results of operations38
  12. Oct 14, 20228-K Shareholder vote39
  13. Feb 13, 2019New chief executive Garry E. Menzel becomes CEO11
  14. May 29, 2015Founded TCR2 THERAPEUTICS INC. is founded2

Calendar

When it reported results

  1. May 11, 2023Reported quarterly or annual results32
  2. Mar 23, 2023Reported quarterly or annual results33
  3. Nov 8, 2022Reported quarterly or annual results38
  4. Aug 8, 2022Reported quarterly or annual results40
  5. May 12, 2022Reported quarterly or annual results41
  6. Mar 22, 2022Reported quarterly or annual results42
  7. Nov 10, 2021Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

143 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 23 major events, 74 insider forms, 8 large holders, 31 other. The latest 20:

  1. Feb 14, 20244 EDGAR
  2. Feb 14, 2024SC 13G/A AMENDMENT NO. 3 EDGAR
  3. Jun 12, 202315-12G EDGAR
  4. Jun 5, 2023EFFECT EDGAR
  5. Jun 5, 2023EFFECT EDGAR
  6. Jun 5, 2023EFFECT EDGAR
  7. Jun 5, 20234 FORM 4 SUBMISSION EDGAR
  8. Jun 5, 20234 FORM 4 SUBMISSION EDGAR
  9. Jun 5, 20234 FORM 4 SUBMISSION EDGAR
  10. Jun 5, 20234 FORM 4 SUBMISSION EDGAR
  11. Jun 1, 2023POS AM EDGAR
  12. Jun 1, 2023POS AM EDGAR
  13. Jun 1, 2023POS AM EDGAR
  14. Jun 1, 2023S-8 POS EDGAR
  15. Jun 1, 2023S-8 POS EDGAR
  16. Jun 1, 2023S-8 POS EDGAR
  17. Jun 1, 2023S-8 POS EDGAR
  18. Jun 1, 2023S-8 POS EDGAR
  19. Jun 1, 20234 OWNERSHIP DOCUMENT EDGAR
  20. Jun 1, 20234 OWNERSHIP DOCUMENT EDGAR

The 143 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 9 buys and 33 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 25, 2023TANG CAPITAL PARTNERS LP10% ownerBuy50,000$1.72$86.0KForm 4
May 22, 2023MPM ASSET MANAGEMENT LLC10% ownerSale70,170$1.88$131.9KForm 4
May 22, 2023GADICKE ANSBERTDirectorSale70,170$1.88$131.9KForm 4
May 12, 2023TANG KEVIN C10% ownerBuy6,183$1.95$12.1KForm 4
May 11, 2023TANG KEVIN C10% ownerBuy38,765$1.95$75.6KForm 4
May 10, 2023TANG CAPITAL PARTNERS LP10% ownerBuy6,774$1.95$13.2KForm 4
May 9, 2023TANG CAPITAL PARTNERS LP10% ownerBuy20,141$1.95$39.3KForm 4
May 8, 2023TANG CAPITAL PARTNERS LP10% ownerBuy57,073$1.95$111.3KForm 4
May 5, 2023TANG CAPITAL PARTNERS LP10% ownerBuy166,823$1.92$319.8KForm 4
May 4, 2023TANG CAPITAL PARTNERS LP10% ownerBuy104,241$1.86$193.9KForm 4
May 3, 2023TANG CAPITAL PARTNERS LP10% ownerBuy18,513$1.85$34.2KForm 4
Dec 13, 2022Cardama Alfonso QuintasChief Medical OfficerSale4,752$1.06$5.0KForm 4
Dec 13, 2022Olagunju PeterChief Operating OfficerSale1,659$1.07$1.8KForm 4
Dec 13, 2022Menzel Garry EPresident and CEOSale11,000$1.06$11.7KForm 4
Dec 12, 2022Cardama Alfonso QuintasChief Medical OfficerSale4,586$1.10$5.0KForm 4
Dec 12, 2022Olagunju PeterChief Operating OfficerSale1,610$1.10$1.8KForm 4
Dec 12, 2022Justice AngelaChief People OfficerSale5,828$1.08$6.3KForm 4
Dec 12, 2022Menzel Garry EPresident and CEOSale10,613$1.10$11.7KForm 4
Dec 9, 2022Cardama Alfonso QuintasChief Medical OfficerSale4,461$1.13$5.0KForm 4
Dec 9, 2022Olagunju PeterChief Operating OfficerSale1,561$1.13$1.8KForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How TCR2 THERAPEUTICS INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTCR2 THERAPEUTICS INC.1
  • CIK0001750019
  • Employer ID (EIN)47-41527511
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 Binney Street, Cambridge, MA 021421
  • Phone617-949-52001
  • Shares outstanding39,261,745 as of May 1, 202310
  • Public float$89.6B as of Jun 30, 20227
  • On EDGAR sinceSep 7, 20181
  • Filings318 in all: 4 (126), 8-K (50), 3 (24), 10-Q (13), SC 13G/A (12), 425 (10), SC 13G (9), DEFA14A (6)1
    All 38 form types

    EFFECT (6), 10-K (5), 424B5 (5), CORRESP (5), S-8 (5), S-8 POS (5), DEF 14A (4), POS AM (4), UPLOAD (4), DRSLTR (3), DRS/A (2), S-1/A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), DEFM14A (1), DRS (1), FWP (1), POSASR (1), S-1 (1), S-3 (1), S-3/A (1), S-3ASR (1), S-3MEF (1), SC 13D (1), SC TO-I (1), SC TO-I/A (1)

  • Latest filingsAnnual report (10-K) Mar 23, 2023
    Quarterly report (10-Q) May 11, 2023
    Proxy statement (DEF 14A) Sep 1, 2022
    Latest 8-K (8-K) Jun 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48